Abstract:Objective: to investigate the clinical effect and adverse reaction of salbutamol combined with montelukast in the treatment of asthma in children. Methods: 74 children with asthma received in our hospital from July 2018 to July 2019 were randomly divided into observation group (n = 37) and control group (n = 37). The control group was treated with salbutamol, salbutamol combined with montelukast in the observation group. The changes of cytokine level, immune function index and pulmonary function index were compared, and the regression time of clinical symptoms and signs and hospital stay were compared. The clinical efficacy and adverse reactions of the two groups were compared. Results: after treatment, the two groups After treatment, the content of serum IL-5 and IL-12 in the observation group was lower than that in the control group (P < 0.05), the content of serum IgA,IgM in the observation group was higher than that in the control group (P < 0.05), and the level of FEV1,FVC and FEV1/ FVC in the observation group was higher than that in the control group after treatment (P < 0.05). The regression time and hospitalization time of clinical symptoms and signs in the observation group were lower than those in the control group (P < 0.05). The scores of cough, dyspnea and chest tightness in the observation group were lower than those in the control group (P < 0.05). The incidence of adverse reactions in the observation group was 10.81% lower than that in the control group (27.02%, P < 0.05). Conclusion: salbutamol combined with montelukast can significantly reduce the level of inflammatory factors, improve immunity and reduce adverse reactions in children with asthma. The clinical effect is significant, which is beneficial to promote recovery and has clinical application value.